Women choosing active surveillance for early breast cancer have similar survival to those who had immediate surgery
Ductal carcinoma in situ (DCIS) — sometimes called 'stage 0' breast cancer — is a pre-invasive condition where cancer cells are confined to milk ducts and haven't spread. For years, standard treatment was surgery (lumpectomy or mastectomy), but many researchers have questioned whether DCIS…
Women choosing active surveillance for early breast cancer have similar survival to those who had immediate surgery
Ductal carcinoma in situ (DCIS) — sometimes called 'stage 0' breast cancer — is a pre-invasive condition where cancer cells are confined to milk ducts and haven't spread. For years, standard treatment was surgery (lumpectomy or mastectomy), but many researchers have questioned whether DCIS uniformly needs immediate treatment, since many cases never progress to invasive cancer.
This randomized trial compared active surveillance (watchful waiting without immediate surgery) to immediate surgery in women with DCIS. The landmark result: women in the active surveillance group had similar ipsilateral invasive breast cancer survival — meaning they were not more likely to die from invasive breast cancer — compared to those who had surgery right away.
This is a major finding that moves the field closer to accepting active surveillance as a legitimate option for appropriately selected DCIS patients, potentially sparing thousands of women unnecessary surgery and its associated harms.
Key Findings
- Active surveillance for DCIS resulted in similar ipsilateral invasive breast cancer survival as immediate surgery
- Randomized trial design provides high-quality evidence
- Active surveillance could safely avoid surgery for appropriately selected DCIS patients
- Trial moves active surveillance closer to being a standard management option
- Investigators noted active surveillance is 'not quite there' yet as universal standard — selection criteria matter
Implications
These results support offering active surveillance as an option to patients with DCIS after thorough discussion of risks and benefits. Oncologists and patients should have the conversation about surveillance as a legitimate alternative to surgery for appropriate candidates, particularly older patients or those with low-risk DCIS features. This could significantly reduce surgical overtreatment.
Caveats
News summary only; trial details including follow-up duration, patient selection criteria, and endpoints not fully available. 'Similar survival' may have confidence intervals that still include clinically meaningful differences — full trial data needed. Active surveillance requires reliable patient follow-up and access to monitoring. Summary based on abstract only.
Source: MedPage Hematology/Oncology — 2026-03-29
